ATE216591T1 - Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind - Google Patents

Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind

Info

Publication number
ATE216591T1
ATE216591T1 AT99303729T AT99303729T ATE216591T1 AT E216591 T1 ATE216591 T1 AT E216591T1 AT 99303729 T AT99303729 T AT 99303729T AT 99303729 T AT99303729 T AT 99303729T AT E216591 T1 ATE216591 T1 AT E216591T1
Authority
AT
Austria
Prior art keywords
antivirals
infection
patients
combination therapy
interferon alpha
Prior art date
Application number
AT99303729T
Other languages
German (de)
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE216591(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE216591T1 publication Critical patent/ATE216591T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT99303729T 1998-05-15 1999-05-13 Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind ATE216591T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ATE216591T1 true ATE216591T1 (de) 2002-05-15

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99303729T ATE216591T1 (de) 1998-05-15 1999-05-13 Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind

Country Status (22)

Country Link
EP (3) EP0956861B1 (https=)
JP (2) JP5281726B2 (https=)
KR (1) KR100694345B1 (https=)
CN (1) CN1230198C (https=)
AR (1) AR019551A1 (https=)
AT (1) ATE216591T1 (https=)
AU (2) AU766597B2 (https=)
BR (1) BR9910505A (https=)
CA (1) CA2331823A1 (https=)
CZ (1) CZ300540B6 (https=)
DE (1) DE69901321T2 (https=)
DK (1) DK0956861T3 (https=)
ES (1) ES2172288T3 (https=)
HU (1) HU230432B1 (https=)
IL (3) IL139220A0 (https=)
MY (1) MY129244A (https=)
NO (1) NO330715B1 (https=)
NZ (1) NZ507621A (https=)
PT (1) PT956861E (https=)
SK (1) SK288038B6 (https=)
TW (1) TWI277424B (https=)
WO (1) WO1999059621A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
KR20030032908A (ko) * 1999-12-23 2003-04-26 아이씨엔 파마슈티컬스, 인코포레이티드 Ｌ-누클레오시드, ｌ-누클레오티드 및 이들의 유사체에대한 조성물 및 방법
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312271A (pt) 2002-06-28 2007-11-06 Idenix Cayman Ltd compostos, composições e seus usos para o tratamento de infecções por flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
JP2006528679A (ja) * 2003-04-01 2006-12-21 インターミューン インコーポレイテッド コロナウイルス感染症及びサースを治療するための組成物及び方法
US20070026014A1 (en) * 2003-04-17 2007-02-01 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1641485A4 (en) * 2003-06-09 2009-06-24 Genome Inst Of Singapore INHIBITION OF SARS CORONAVIRUS INFECTION USING ANTIVIRAL DRUGS CLINICALLY TESTED
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2175865A4 (en) 2007-07-25 2012-01-11 Biolex Therapeutics Inc INTERFERON DRUG PRODUCTS WITH CONTROLLED RELEASE AND TREATMENT OF HCV INFECTIONS THEREWITH
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
JP2013542206A (ja) * 2010-10-05 2013-11-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
DK1136075T3 (da) * 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion

Also Published As

Publication number Publication date
EP2305287A1 (en) 2011-04-06
WO1999059621A1 (en) 1999-11-25
AR019551A1 (es) 2002-02-27
CA2331823A1 (en) 1999-11-25
CN1309568A (zh) 2001-08-22
HU230432B1 (hu) 2016-06-28
JP5281726B2 (ja) 2013-09-04
JP2011173898A (ja) 2011-09-08
SK288038B6 (en) 2013-01-02
DE69901321D1 (de) 2002-05-29
CN1230198C (zh) 2005-12-07
KR20010043624A (ko) 2001-05-25
HUP0103423A2 (hu) 2002-01-28
AU766597B2 (en) 2003-10-16
AU2005220271A1 (en) 2005-11-03
HUP0103423A3 (en) 2003-11-28
EP0956861A1 (en) 1999-11-17
IL139220A0 (en) 2001-11-25
AU2005220271B8 (en) 2010-11-18
KR100694345B1 (ko) 2007-03-12
MY129244A (en) 2007-03-30
AU2005220271B9 (en) 2010-12-09
IL207259A (en) 2016-08-31
ES2172288T3 (es) 2002-09-16
PT956861E (pt) 2002-08-30
DK0956861T3 (da) 2002-07-01
AU3860099A (en) 1999-12-06
TWI277424B (en) 2007-04-01
NO330715B1 (no) 2011-06-20
EP0956861B1 (en) 2002-04-24
NO20005755D0 (no) 2000-11-14
IL207259A0 (en) 2010-12-30
JP2002515453A (ja) 2002-05-28
BR9910505A (pt) 2001-01-02
NO20005755L (no) 2001-01-12
HK1021131A1 (en) 2000-06-02
AU2005220271B2 (en) 2005-11-03
NZ507621A (en) 2002-11-26
IL139220A (en) 2013-02-28
EP1213029A1 (en) 2002-06-12
DE69901321T2 (de) 2002-12-12
CZ20004177A3 (cs) 2001-04-11
CZ300540B6 (cs) 2009-06-10
SK17102000A3 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
ATE216591T1 (de) Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
DE69801970D1 (de) Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
PT712862E (pt) Acilacao selectiva de grupos epsilon-amino em ensulina
NO20015059D0 (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
SI1576138T1 (sl) 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
DE69016348D1 (de) Leukozyten und Hämoglobin im Blut.
DE68926387D1 (de) Wärmebeständige Kunststoffpaste sowie damit hergestellte integrierte Schaltungsanordnung
ATA22989A (de) Behandlungsliege, insbesondere massageliege
EP0656116A4 (en) METHOD FOR MONITORING THE EFFECTIVENESS OF INTERFERON THERAPY ON HEPATITIS-C INFECTED INDIVIDURES.
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
BR6900836U (pt) Disposicao introduzida em conjunto de mesa e cadeiras
BR9202811A (pt) Aperfeicoamento aplicado em jogo recreativo de mesa
BR7001287U (pt) Disposicao introduzida em prancha ajustavel degrau aerobico e muscular
BR7000950U (pt) Utensilio aplicavel em ginastica terapeutica e estetica facial
BR6800609U (pt) Conjunto de cadeira,mesa e lousa
HUP0200731A3 (en) Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
BR8801541A (pt) Aperfeicoamento em panelas,dispositivo e revestimento descartavel
BR8806886A (pt) Aperfeicoamento em jogo de futebol de mesa
BR8900388A (pt) Dispositivo articulador e fixador de mesa de seno
UA25146A (uk) Спосіб раhhьої діагhостики уражеhь пареhхіматозhих оргаhів у осіб, які коhтактують з епоксидhими сполуками
BR7100119U (pt) Disposicao introduzida em mesa